|
1
|
Bozkurt B and Mann DL: Use of biomarkers
in the management of heart failure: Are we there yet? Circulation.
107:1231–1233. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jortani SA, Prabhu SD and Valdes R Jr:
Strategies for developing biomarkers of heart failure. Clin Chem.
50:265–278. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Harrison A and Amundson S: Evaluation and
management of the acutely dyspneic patient: The role of biomarkers.
Am J Emerg Med. 23:371–378. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Costello-Boerrigter LC and Burnett JC Jr:
The prognostic value of N-terminal proB-type natriuretic peptide.
Nat Clin Pract Cardiovasc Med. 2:194–201. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jarolim P: Serum biomarkers for heart
failure. Cardiovasc Pathol. 15:144–149. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aviles JM and Aviles RJ: Advances in
cardiac biomarkers. Emerg Med Clin North Am. 23:959–975. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moe GW: BNP in the diagnosis and risk
stratification of heart failure. Heart Fail Monit. 4:116–122.
2005.PubMed/NCBI
|
|
8
|
Bettencourt P: NT-proBNP and BNP:
Biomarkers for heart failure management. Eur J Heart Fail.
6:359–363. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Richards M and Troughton RW: NT-proBNP in
heart failure: Therapy decisions and monitoring. Eur J Heart Fail.
6:351–354. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fuat A, Murphy JJ, Hungin AP, Curry J,
Mehrzad AA, Hetherington A, Johnston JI, Smellie WS, Duffy V and
Cawley P: The diagnostic accuracy and utility of a B-type
natriuretic peptide test in a community population of patients with
suspected heart failure. Br J Gen Pract. 56:327–333.
2006.PubMed/NCBI
|
|
11
|
Moe GW: B-type natriuretic peptide in
heart failure. Curr Opin Cardiol. 21:208–214. 2006.PubMed/NCBI
|
|
12
|
Palazzuoli A, Gallotta M, Quatrini I and
Nuti R: Natriuretic peptides (BNP and NT-proBNP): Measurement and
relevance in heart failure. Vasc Health Risk Manag. 6:411–418.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
McKie PM, Rodeheffer RJ, Cataliotti A,
Martin FL, Urban LH, Mahoney DW, Jacobsen SJ, Redfield MM and
Burnett JC Jr: Amino-terminal pro-B-type natriuretic peptide and
B-type natriuretic peptide: Biomarkers for mortality in a large
community-based cohort free of heart failure. Hypertension.
47:874–880. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maisel AS, Krishnaswamy P, Nowak RM,
McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu
AH, et al: Rapid measurement of B-type natriuretic peptide in the
emergency diagnosis of heart failure. N Engl J Med. 347:161–167.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hayek S and Nemer M: Cardiac natriuretic
peptides: From basic discovery to clinical practice. Cardiovasc
Ther. 29:362–376. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Valle R and Aspromonte N: Use of brain
natriuretic peptide and bioimpedance to guide therapy in heart
failure patients. Contrib Nephrol. 164:209–216. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
van Kimmenade RR, Januzzi JL Jr, Bakker
JA, Houben AJ, Rennenberg R, Kroon AA, Crijns HJ, van
Dieijen-Visser MP, de Leeuw PW and Pinto YM: Renal clearance of
B-type natriuretic peptide and amino terminal pro-B-type
natriuretic peptide a mechanistic study in hypertensive subjects. J
Am Coll Cardiol. 53:884–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tagore R, Ling LH, Yang H, Daw HY, Chan YH
and Sethi SK: Natriuretic peptides in chronic kidney disease. Clin
J Am Soc Nephrol. 3:1644–1651. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bednarek-Skublewska A, Zaluska W and
Ksiazek A: The relationship between serum level of N-terminal
pro-B-type natriuretic peptide and nutritional status, and
inflammation in chronic hemodialysis patients. Clin Nephrol.
73:14–20. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nishiyama K, Tsutamoto T, Tanaka T, Fujii
M, Yamamoto T, Yamaji M and Horie M: Plasma NT-proBNP as a more
reliable biomarker of endogenous cardiac natriuretic peptides than
BNP during carperitide infusion. Int Heart J. 50:183–190. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jensen J, Ma LP, Fu ML, Svaninger D,
Lundberg PA and Hammarsten O: Inflammation increases NT-proBNP and
the NT-proBNP/BNP ratio. Clin Res Cardiol. 99:445–452. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
De Bold AJ: Atrial natriuretic factor: A
hormone produced by the heart. Science. 230:767–770. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Clerico A, Iervasi G, Del Chicca MG, Emdin
M, Maffei S, Nannipieri M, Sabatino L, Forini F, Manfredi C and
Donato L: Circulating levels of cardiac natriuretic peptides (ANP
and BNP) measured by highly sensitive and specific
immunoradiometric assays in normal subjects and in patients with
different degrees of heart failure. J Endocrinol Invest.
21:170–179. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rienstra M, Van Gelder IC, Van den Berg
MP, Boomsma F and Van Veldhuisen DJ: Natriuretic peptides in
patients with atrial fibrillation and advanced chronic heart
failure: Determinants and prognostic value of (NT-)ANP and
(NT-pro)BNP. Europace. 8:482–487. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Falcão LM, Pinto F, Ravara L and van
Zwieten PA: BNP and ANP as diagnostic and predictive markers in
heart failure with left ventricular systolic dysfunction. J Renin
Angiotensin Aldosterone Syst. 5:121–129. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vanderheyden M, Bartunek J, Filippatos G,
Goethals M, Vlem BV and Maisel A: Cardiovascular disease in
patients with chronic renal impairment: Role of natriuretic
peptides. Congest Heart Fail. 14 4 Suppl 1:1–42. 2008. View Article : Google Scholar
|
|
27
|
Bayes-Genis A, DeFilippi C and Januzzi JL
Jr: Understanding amino-terminal pro-B-type natriuretic peptide in
obesity. Am J Cardiol. 101:89–94. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sugisawa T, Kishimoto I, Kokubo Y, Makino
H, Miyamoto Y and Yoshimasa Y: Association of plasma B-type
natriuretic peptide levels with obesity in a general urban Japanese
population: The Suita Study. Endocr J. 57:727–733. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Srisawasdi P, Vanavanan S,
Charoenpanichkit C and Kroll MH: The effect of renal dysfunction on
BNP, NT-proBNP, and their ratio. Am J Clin Pathol. 133:14–23. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kälsch H, Neumann T and Erbel R: Less
increase of BNP and NT-proBNP levels in obese patient with
decompensated heart failure: Interpretation of natriuretic peptides
in obesity. Int J Cardiol. 133:e22–e24. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
deFilippi CR, Seliger SL, Maynard S and
Christenson RH: Impact of renal disease on natriuretic peptide
testing for diagnosing decompensated heart failure and predicting
mortality. Clin Chem. 53:1511–1519. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
DeFilippi C, van Kimmenade RR and Pinto
YM: Amino-terminal pro-B-type natriuretic peptide testing in renal
disease. Am J Cardiol. 101:82–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
McCullough PA and Sandberg KR: B-type
natriuretic peptide and renal disease. Heart Fail Rev. 8:355–358.
2003. View Article : Google Scholar : PubMed/NCBI
|
